Skip to main content

Table 1 Summary of gene signatures in the study and the annotation mapping coverage

From: Systematic assessment of prognostic gene signatures for breast cancer shows distinct influence of time and ER status

Signature Description Validation Training platform Coverage (%)
Intrinsic [1, 21] Intrinsic subtype Ref. [2, 3] Stanford cDNA array 410/549 (75%)
PAM50 [9] PAM50 subtype Ref. [9] Agilent Human oligo array 42/50 (84%)
70gene [4] MammaPrint Ref. [5, 2224] Agilent 25 k Human oligo array 46/70 (65.7%)
76gene [6] Veridex Ref. [25, 26] Affymetrix u133a GeneChip 76/76 (100%)
Hypoxia [30] Hypoxia signature Ref. [15, 30] Stanford cDNA array 117/253 (46.2%)a
WR [28] Wound response Ref. [15, 29] Stanford cDNA array 298/380 (78.4%)
GGI [7] Genomic Grade Index Ref. [17, 27] Affymetrix u133a GeneChip 128/128 (100%)
RS [12] OncoType DX Recurrent Score Ref. [12, 31] qRT-PCR 21/21 (100%)
EP [32] EndoPredict risk score Ref. [32, 40] qRT-PCR 11/11 (100%)
  1. aThe original study [30] reported 168 UniGene IDs annotated from 253 clones in the Hypoxia signature, of which 117 clones mapped to the Affy probes (46.2%). Considering these mapped clones represented 116 unique Unigene clusters (under UniGene Build Number 222), the mapping coverage for this signature on the studied data is higher than the percentage reported here.